Actions

Acute leukaemia types: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
(10 intermediate revisions by the same user not shown)
Line 16: Line 16:
<div style="width: 100%; border: 1px solid black; font-size:100%">
<div style="width: 100%; border: 1px solid black; font-size:100%">
{| class="wikitable" style="color:black; background-color:#ffffff;" cellpadding="0"
{| class="wikitable" style="color:black; background-color:#ffffff;" cellpadding="0"
!colspan="2" <span style="font-size:90%; text-align:center; border: 1px solid black; background:pale gray">|'''MARKERS USEFUL TO CONFIRM PRIMITIVE NATURE OF BLAST CELLS'''</br></span>
!colspan="2" <span style="font-size:90%; font-color:navy; text-align:center; border: 1px solid black; background:pale gray">|'''MARKERS USEFUL TO CONFIRM PRIMITIVE NATURE OF BLAST CELLS'''</br></span>
|-
|-
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |Useful markers of primitive nature
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Useful markers of primitive nature'''
<div class="mw-collapsible mw-collapsed" data-expandtext="Click for explanation" data-collapsetext="Hide explanation">
<div class="mw-collapsible mw-collapsed" data-expandtext="Click for explanation" data-collapsetext="Hide explanation">
<div class="mw-collapsible-content">
<div class="mw-collapsible-content">
<span style="font-size:80%;></br>The first step in AML diagnosis to establish the primitive nature of the abnormal cells:</br>
<span style="font-size:80%;></br>The first step in AML diagnosis to establish the primitive nature of the abnormal cells:</br>


<span style="font-size:80%;>'''(1)''' Typically AML blasts have low CD45 expression and cause low side scatter. This means that they form a relatively uniform and distinctive population that is clearly separate from that of lymphocytes on CD45/SSc plots ([[CD45|for further details see this section]]) also not all AML forms may fit this pattern - particularly [[APL]] and [[monocytic AML]].</br>
<span style="font-size:80%;>'''(1)''' Typically AML blasts have low CD45 expression and cause low side scatter. This means that they form a relatively uniform and distinctive population that is clearly separate from that of lymphocytes on CD45/SSc plots ([[CD45|for further details see this section]]). It is important to realise however also not all AML cases may fit this pattern low CD45/low SSc pattern - particularly [[APL]] and [[monocytic AML]].</br>
<span style="font-size:80%;>'''(2)''' Additional markers often expressed on myeloid cells may help confirm the primitive nature of the cells: in AML this is most often CD34, although other markers may contribute.</br>
<span style="font-size:80%;>'''(2)''' Additional markers often expressed on myeloid cells may help confirm the primitive nature of the cells: in AML this is most often CD34, although other markers may contribute and are also listed.</br>
</span>
</span>
</div></div></div>
</div></div></div>
Line 33: Line 33:
|colspan="1" style = "font-size:90%; color:black;" |'''[[CD34]]'''
|colspan="1" style = "font-size:90%; color:black;" |'''[[CD34]]'''
|colspan="1" style = "font-size:84%;"|Frequently expressed by AML blast cells (40-80% of cases) - most often in less differentiated forms of AML. Expression is also seein frequently (and often more strongly) in ALL'''
|colspan="1" style = "font-size:84%;"|Frequently expressed by AML blast cells (40-80% of cases) - most often in less differentiated forms of AML. Expression is also seein frequently (and often more strongly) in ALL'''
|-
|colspan="2" style = "font-size:90%; color:black; background:#eedddd" |Other markers that may be associated with primitive nature in AML
|-
|colspan="2" style = "font-size:90%;|In the context of a proven AML diagnosis a number of markers may be expressed that are considered to predominantly reflect their primitive nature. Some of these are more frequently associated with lymphoid disorders, but providing other criteria for AML are met their presence does not change lineage assignment. These include [[TDT]], [[CD7]], other?
|-
|-
|}
|}
Line 52: Line 56:
|-
|-
|colspan="1" style = "font-size:90%; color:black;" |'''[[MPO]]'''
|colspan="1" style = "font-size:90%; color:black;" |'''[[MPO]]'''
|colspan="1" style = "font-size:84%;"|A strong lineage marker for AML (expressed in around 80% of cases) but generally in those with granulocytic maturation. When detected by flow cytometry is diagnostic of myeloid differentiation (either AML or MPAL)
|colspan="1" style = "font-size:84%;"|A '''lineage-defining''' marker in AML when expressed (around 80% of cases). More frequent in cases with granulocytic maturation. When detected by flow cytometry is diagnostic of myeloid differentiation (either AML or MPAL)
|-
|-
|colspan="1" style = "font-size:90%; color:black;" |'''[[CD117]]'''
|colspan="1" style = "font-size:90%; color:black;" |'''[[CD117]]'''
Line 183: Line 187:
|colspan="2" style = "font-size:90%; color:black;" |'''Mixed Phenotype Acute leukaemia (MPAL)'''
|colspan="2" style = "font-size:90%; color:black;" |'''Mixed Phenotype Acute leukaemia (MPAL)'''
|-
|-
|colspan="2" style = "font-size:84%;"|Formerly known as leukaemia of ambiguous lineage
|colspan="2" style = "font-size:84%;"|Formerly known as leukaemia of ambiguous lineage: Myeloid MPO or monocytic defined by at least two markers (CD14, CD11c, CD64, NSE, lysozyme. T lineage CD3 (s or m), STRONG Cd19, with strong CD79a cCD22 or CD10 OR wk CD19 also with obove
|-
|-
|colspan="2" style = "font-size:90%; color:black;" |'''Early T-precursor acute lymphoblastic leukaemia (ETP-ALL)'''
|colspan="2" style = "font-size:90%; color:black;" |'''Early T-precursor acute lymphoblastic leukaemia (ETP-ALL)'''
|-
|colspan="2" style = "font-size:84%;"|A (relatively new entity)
|-
|colspan="2" style = "font-size:90%; color:black;" |'''Undifferentiated acute leukaeemia'''
|-
|-
|colspan="2" style = "font-size:84%;"|A (relatively new entity)  
|colspan="2" style = "font-size:84%;"|A (relatively new entity)  

Revision as of 10:21, 26 July 2023


Sections

  • Establishing the primitive nature of AML blast cells (CD45 gating and primitive markers) click to visit section
  • The AML phenotype (expected markers expressed by most AML cases or those with specific differetiation) click to visit section
  • Abberent markers in AML (Abberrent makers that are frequently encountered) click to visit section
  • Important additional notes 1: recognising difficult subtypes 2: clues suggesting MPAL or ETP-ALL) click to visit section


(note: for further information on any marker or section click the blue highlighted text)



.

MARKERS USEFUL TO CONFIRM PRIMITIVE NATURE OF BLAST CELLS
Useful markers of primitive nature


The first step in AML diagnosis to establish the primitive nature of the abnormal cells:

(1) Typically AML blasts have low CD45 expression and cause low side scatter. This means that they form a relatively uniform and distinctive population that is clearly separate from that of lymphocytes on CD45/SSc plots (for further details see this section). It is important to realise however also not all AML cases may fit this pattern low CD45/low SSc pattern - particularly APL and monocytic AML.
(2) Additional markers often expressed on myeloid cells may help confirm the primitive nature of the cells: in AML this is most often CD34, although other markers may contribute and are also listed.

CD45 A marker expressed by all leukocytes and their precursors. In AML expression is characteristically "weak" i.e. significantly less intense than normal lymphocytes or monocytes. In monocytic AML expression may be stronger.
CD34 Frequently expressed by AML blast cells (40-80% of cases) - most often in less differentiated forms of AML. Expression is also seein frequently (and often more strongly) in ALL
Other markers that may be associated with primitive nature in AML
In the context of a proven AML diagnosis a number of markers may be expressed that are considered to predominantly reflect their primitive nature. Some of these are more frequently associated with lymphoid disorders, but providing other criteria for AML are met their presence does not change lineage assignment. These include TDT, CD7, other?

.

MARKERS USEFUL TO CONFIRM MYELOID LINEAGE OR DIFFERENTIATION
Frequently expressed "general" markers of myeloid lineage


Some additional markers are regarded as indicating primitive nature when expressed by AML blasts; these markers may be more usually assocated with T-lineage or B-lineage ALL, but when expressed in AML they are considered to indicate less differentiated forms.

MPO A lineage-defining marker in AML when expressed (around 80% of cases). More frequent in cases with granulocytic maturation. When detected by flow cytometry is diagnostic of myeloid differentiation (either AML or MPAL)
CD117 An early marker of myeloid lineage, seen in up to 80% of AML and vauable in recognising more primitive differentaiion forms (note that aberrant expression is seen in up to 20% of ALL cases)
CD33 A good marker for AML, particularly for those cases with granulocytic maturation, CD33 is often less strongly expressed in AML with monocytic dfferentiation and strongly expressed in APL.
CD13 A good lineage marker for AML that is acquired a little later in differentation than CD117 or CD33; expression of CD13 is often higher than CD33 in AML with monocytic differentiation.
Confirmatory markers of AML or markers of subtype


Some additional markers are regarded as indicating primitive nature when expressed by AML blasts; these markers may be more usually assocated with T-lineage or B-lineage ALL, but when expressed in AML they are considered to indicate less differentiated forms.

Granulocytic lineage markers
CD10 One of tne of the first lineage-markers acquired in AML with good relative specificity
CD11b One of tne of the first lineage-markers acquired in AML with good relative specificity
Monocytic lineage markers
CD11c One of tne of the first lineage-markers acquired in AML with good relative specificity
CD14 A good marker for AML that is often less strongly expressed in monocytic forms
CD64 A good lineage marker for AML aquired a little later, higher than CD13 in monocytic forms
Erythroid lineage markers
CD14 A good marker for AML that is often less strongly expressed in monocytic forms
CD64 A good lineage marker for AML aquired a little later, higher than CD13 in monocytic forms
Megakaryocytic lineage markers
CD14 A good marker for AML that is often less strongly expressed in monocytic forms
CD64 A good lineage marker for AML aquired a little later, higher than CD13 in monocytic forms


.

NON MYELOID MARKERS FREQUENTLY "ABERENTLY" EXPRESSED IN AML
Markers of lymphoid lineage indicating primitive dfferentiation in AML


Some additional markers are regarded as indicating primitive nature when expressed by AML blasts; these markers may be more usually assocated with T-lineage or B-lineage ALL, but when expressed in AML they are considered to indicate less differentiated forms.

TDT Expressed in some cases of AML (5-20%) particularly in less differentiated blast cells, often on a sub-population of cells. More typically associated with primitive ALL blast cells.
CD7 Predominantly seen as a T-cell antigen, CD7 tends may be expressed by AML blasts (20-40%) where it most often indicates a more primitive forms or MPAL. CD7 is most consistently a marker of T-lineage (including T-ALL and more mature froms).
Markers of lymphoid differentation abererantly expressed in AML


Some additional markers are regarded as indicating primitive nature when expressed by AML blasts; these markers may be more usually assocated with T-lineage or B-lineage ALL, but when expressed in AML they are considered to indicate less differentiated forms.

TDT Expressed in some cases of AML (5-20%) particularly in less differentiated blast cells, often on a sub-population of cells. More typically associated with primitive ALL blast cells.
CD7 Predominantly seen as a T-cell antigen, CD7 tends may be expressed by AML blasts (20-40%) where it most often indicates a more primitive forms or MPAL. CD7 is most consistently a marker of T-lineage (including T-ALL and more mature froms).


.

IMPORTANT ADDITIONAL POINTS
AML subtypes with distinctive phenotype


The first step in AML diagnosis to establish the primitive nature of the abnormal cells:

(1) Typically AML blasts have low CD45 expression and cause low side scatter. This means that they form a relatively uniform and distinctive population that is clearly separate from that of lymphocytes on CD45/SSc plots (for further details see this section) also not all AML forms may fit this pattern - particularly APL and monocytic AML.
(2) Additional markers often expressed on myeloid cells may help confirm the primitive nature of the cells: in AML this is most often CD34, although other markers may contribute.

Mixed Phenotype Acute leukaemia (MPAL)
Formerly known as leukaemia of ambiguous lineage
Early T-precursor acute lymphoblastic leukaemia (ETP-ALL)
A (relatively new entity)
Acute leukaemia types with features of mixed phenotype


The first step in AML diagnosis to establish the primitive nature of the abnormal cells:

(1) Typically AML blasts have low CD45 expression and cause low side scatter. This means that they form a relatively uniform and distinctive population that is clearly separate from that of lymphocytes on CD45/SSc plots (for further details see this section) also not all AML forms may fit this pattern - particularly APL and monocytic AML.
(2) Additional markers often expressed on myeloid cells may help confirm the primitive nature of the cells: in AML this is most often CD34, although other markers may contribute.

Mixed Phenotype Acute leukaemia (MPAL)
Formerly known as leukaemia of ambiguous lineage: Myeloid MPO or monocytic defined by at least two markers (CD14, CD11c, CD64, NSE, lysozyme. T lineage CD3 (s or m), STRONG Cd19, with strong CD79a cCD22 or CD10 OR wk CD19 also with obove
Early T-precursor acute lymphoblastic leukaemia (ETP-ALL)
A (relatively new entity)
Undifferentiated acute leukaeemia
A (relatively new entity)
Non-haematopoietic tumours
need to know problems